Company news
Vyne Therapeutics Inc. (NASDAQ:VYNE) news
Vyne Therapeutics Inc. news releases on 6ix. Latest, Jul 23, 2026: VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split…
Press releases & updates
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
July 23, 2026
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
July 21, 2026
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
July 10, 2026
VYNE Therapeutics : Yarrow Bioscience Investor Presentation
May 21, 2026
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
December 17, 2025
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
December 16, 2025
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
November 6, 2025
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
August 14, 2025
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
July 30, 2025
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
July 2, 2025
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
May 8, 2025
VYNE Therapeutics Provides Update on VYN202 Program
April 25, 2025
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2025
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
March 6, 2025
VYNE Therapeutics to Participate in March Investor Conferences
February 20, 2025
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
February 19, 2025
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
January 5, 2025
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
December 22, 2024
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
September 11, 2024
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
July 15, 2024
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
July 8, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
June 12, 2024
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
June 4, 2024
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
May 5, 2024
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
April 30, 2024
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
February 28, 2024
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
January 9, 2024
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
January 2, 2024
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 12, 2023
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
November 6, 2023
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
October 31, 2023
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
October 29, 2023
VYNE Therapeutics Announces Private Placement of $88 Million
October 29, 2023
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
October 29, 2023
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
April 30, 2023
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
April 18, 2023
VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201
March 29, 2023
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
March 8, 2023
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
February 27, 2023
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
February 14, 2023
VYNE Therapeutics Announces Reverse Stock Split
February 9, 2023
VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
January 8, 2023
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
December 6, 2022
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
November 16, 2022
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022